Who owns Corvus Pharmaceuticals, Inc. (CRV)? Elite investor 13F holders
3 tracked elite investors reported holding Corvus Pharmaceuticals, Inc as of 2026-06-30, including D.E. Shaw, Ancora Advisors / Ancora Holdings, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | CORVUS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1989664.00 USD | 133177.000000 | Shares | buy | Original filing |
| Renaissance Technologies LLC | CORVUS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Ancora Advisors / Ancora Holdings | CORVUS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 847442.00 USD | 56723.000000 | Shares | add | Original filing |
| Tudor Investment | CORVUS PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 328560.00 USD | 21992.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.